Oncolytics Biotech (US:ONCY) Prnewswire·2024-12-18 12:00Core Insights - Oncolytics Biotech Inc. announced the acceptance of two abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, highlighting the potential of pelareorep in treating difficult gastrointestinal cancers [1][2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in various cancer studies [3][4] - Pelareorep works by inducing anti-cancer immune responses and converting "cold" tumors into "hot" tumors, enhancing the effectiveness of existing cancer treatments [3] Clinical Data Presentation - The first abstract, titled "GOBLET platform study," will present preliminary safety and tumor response results for relapsed anal carcinoma patients treated with pelareorep and atezolizumab, scheduled for January 25, 2025 [2] - The second abstract, titled "GOBLET study," will discuss safety run-in results for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep combined with modified FOLFIRINOX and/or atezolizumab, scheduled for January 24, 2025 [2] Regulatory and Clinical Development - Oncolytics is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]